Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial
Background: Previous investigations have indicated the potential of mesenchymal stem cell (MSC) transplantation in treating COVID-19. However, the limited lifespan of transplanted cells constrains this therapeutic approach. the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Advanced Biomedical Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/abr.abr_477_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156687821897728 |
|---|---|
| author | Masoumeh Baghalishahi Maysam Yousefi Seyed Noureddin Nematollahi-Mahani Mahsa Ziasistani Fahimeh Pourjafari Mona Saheli |
| author_facet | Masoumeh Baghalishahi Maysam Yousefi Seyed Noureddin Nematollahi-Mahani Mahsa Ziasistani Fahimeh Pourjafari Mona Saheli |
| author_sort | Masoumeh Baghalishahi |
| collection | DOAJ |
| description | Background:
Previous investigations have indicated the potential of mesenchymal stem cell (MSC) transplantation in treating COVID-19. However, the limited lifespan of transplanted cells constrains this therapeutic approach. the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs secretome could be a promising solution to improve patient outcomes.
Materials and Methods:
A randomized clinical trial was conducted in Kerman, a region in south-central Iran. This study enrolled twenty patients in the severe phase of COVID-19 pneumonia, randomly allocated into either investigation or control groups. Both groups received standard therapy, the investigation group additionally received nebulized concentrated MSCs secretome, 2 mL administered twice daily for five consecutive days. To evaluate the effect of MSCs secretome therapy, the length of stay in the intensive care unit (ICU), oximetry, and paraclinical results were assessed at baseline and 5 days after ICU admission.
Results:
Baseline characteristics were balanced and distributed among the two groups. No adverse effect was observed in MSCs secretome-treated patients. Compared to the control group, the investigated group exhibited a decrease in ICU stay duration (10.90 ± 3.75 vs. 5.50 ± 1.64 days, P = 0.04) and a significant improvement in O2 saturation (60.65 ± 16.58 vs. 79.47 ± 15.36, P = 0.02). In addition, significant decreases in CRP, PTT, and INR and upregulation in lymphocyte fraction were observed in the investigation group during the study period.
Conclusions:
The findings of this study underscore the prospective advantages and safety of the secretome of MSCs as a viable therapeutic choice in COVID-19 patients. We advise verifying our results through additional clinical trials at various disease stages. |
| format | Article |
| id | doaj-art-c335ac8fa63f465d9a8c4b019da1aef7 |
| institution | OA Journals |
| issn | 2277-9175 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Advanced Biomedical Research |
| spelling | doaj-art-c335ac8fa63f465d9a8c4b019da1aef72025-08-20T02:24:25ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752025-05-01141444410.4103/abr.abr_477_23Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled TrialMasoumeh BaghalishahiMaysam YousefiSeyed Noureddin Nematollahi-MahaniMahsa ZiasistaniFahimeh PourjafariMona SaheliBackground: Previous investigations have indicated the potential of mesenchymal stem cell (MSC) transplantation in treating COVID-19. However, the limited lifespan of transplanted cells constrains this therapeutic approach. the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs secretome could be a promising solution to improve patient outcomes. Materials and Methods: A randomized clinical trial was conducted in Kerman, a region in south-central Iran. This study enrolled twenty patients in the severe phase of COVID-19 pneumonia, randomly allocated into either investigation or control groups. Both groups received standard therapy, the investigation group additionally received nebulized concentrated MSCs secretome, 2 mL administered twice daily for five consecutive days. To evaluate the effect of MSCs secretome therapy, the length of stay in the intensive care unit (ICU), oximetry, and paraclinical results were assessed at baseline and 5 days after ICU admission. Results: Baseline characteristics were balanced and distributed among the two groups. No adverse effect was observed in MSCs secretome-treated patients. Compared to the control group, the investigated group exhibited a decrease in ICU stay duration (10.90 ± 3.75 vs. 5.50 ± 1.64 days, P = 0.04) and a significant improvement in O2 saturation (60.65 ± 16.58 vs. 79.47 ± 15.36, P = 0.02). In addition, significant decreases in CRP, PTT, and INR and upregulation in lymphocyte fraction were observed in the investigation group during the study period. Conclusions: The findings of this study underscore the prospective advantages and safety of the secretome of MSCs as a viable therapeutic choice in COVID-19 patients. We advise verifying our results through additional clinical trials at various disease stages.https://journals.lww.com/10.4103/abr.abr_477_23covid-19hospitalizationintensive care unitsmesenchymal stem cellsoximetrysecretome |
| spellingShingle | Masoumeh Baghalishahi Maysam Yousefi Seyed Noureddin Nematollahi-Mahani Mahsa Ziasistani Fahimeh Pourjafari Mona Saheli Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial Advanced Biomedical Research covid-19 hospitalization intensive care units mesenchymal stem cells oximetry secretome |
| title | Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial |
| title_full | Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial |
| title_fullStr | Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial |
| title_full_unstemmed | Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial |
| title_short | Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial |
| title_sort | nebulization of mesenchymal stem cells secretome attenuates acute respiratory distress syndrome caused by sars cov 2 corona virus an open label controlled trial |
| topic | covid-19 hospitalization intensive care units mesenchymal stem cells oximetry secretome |
| url | https://journals.lww.com/10.4103/abr.abr_477_23 |
| work_keys_str_mv | AT masoumehbaghalishahi nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial AT maysamyousefi nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial AT seyednoureddinnematollahimahani nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial AT mahsaziasistani nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial AT fahimehpourjafari nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial AT monasaheli nebulizationofmesenchymalstemcellssecretomeattenuatesacuterespiratorydistresssyndromecausedbysarscov2coronavirusanopenlabelcontrolledtrial |